Account-level
Named hospital, retailer, distributor, or key account — not a country total.
Primary evidence · Account & SKU
Account-level market research data is brand versus competitor evidence cut by customer account — a named hospital, retailer, or distributor — not only a national average. SKU-level data adds the product cut: how this pack or line is doing in that account, in that country. Syndicated IQVIA and Nielsen audits are built for the national feed. Primary fieldwork is how you get the rest, as part of our healthcare market research programmes.
Last updated 2 September 2026 · Sarah Chen
Three cuts
Named hospital, retailer, distributor, or key account — not a country total.
Pack, strength, or line for a named brand in a named country.
Subaccounts, subregions, traditional trade, and account- or SKU-specific primary data.
Account-level market research data is insights cut by customer account, not only national aggregates. SKU-level data is the same evidence cut by product SKU for a named brand in a named country. Syndicated IQVIA and Nielsen feeds typically miss subaccounts, traditional trade, and those cuts — primary fieldwork fills the gap.
Manufacturers brief BioNixus when the dashboard cannot show how their brand stacks up in-market at the account or SKU they actually sell.
Side by side
| Cut | Syndicated (IQVIA / NielsenIQ) | Primary fieldwork (BioNixus) |
|---|---|---|
| National / global aggregate | Yes — core IQVIA and NielsenIQ output | Can reproduce, but usually not the reason to brief |
| Account-level (named hospital, retailer, distributor) | Rarely — modelled or missing | Yes — designed into the sample and the tables |
| SKU-level for a named brand in a named country | Often franchise or category only | Yes — pack, strength, and line cuts |
| Traditional trade / subregion | Typically excluded from modern-trade panels | Fielded when the volume actually moves there |
| Pricing model | Enterprise subscription | Project- and country-based — see pricing |
Where volume still moves
Traditional trade — independent pharmacies, grocers, and non-modern retail — is where a large share of volume still moves in Egypt, the GCC, and other emerging markets. National modern-trade panels and prescription audits are not designed to sample those accounts. Subregion and subaccount cuts sit below the subscription grain. That is why a Head of Marketing can pay for IQVIA or Nielsen and still be blind on how the brand stacks up in-market.
Primary studies fill that gap: mystery shoppers, account interviews, pharmacy and hospital pulls, and surveys designed for the accounts and SKUs in the brief. See IQVIA alternative for pharma audits and Nielsen alternative for FMCG retail measurement.
Different product
CRM and claims software is not primary fieldwork
Searches for “account-level market research data” often return Veeva, Trinity, IntegriChain, or EVERSANA — software that stitches CRM, claims, and payer profiles, mostly for the United States. That is a different product. BioNixus is a primary market research firm: field teams collect account-level and SKU-level evidence for a named brand in a named country, including markets those platforms do not cover.
Account-level market research data is brand or competitor evidence cut by customer account — a named hospital, distributor, retailer, or key account — not only a national or global aggregate. It answers how this brand is doing in these accounts, in this country.
SKU-level competitor data is the same evidence cut by product SKU for a named brand in a named country. It shows which pack, strength, or line is winning or losing inside an account, not just the franchise total.
Syndicated IQVIA and NielsenIQ feeds are built for national, modern-trade, or panel-modelled audits. They typically miss subaccounts, subregions, traditional trade, and account-level or SKU-level primary data. That is a product design choice, not a quality failure.
No. US commercial platforms such as Veeva Link, Trinity, or IntegriChain stitch CRM, claims, and account profiles. BioNixus account-level data is primary fieldwork — interviews, surveys, mystery shoppers, pharmacy and hospital pulls — designed for a named brand in a named country.
Yes. The usual model is the syndicated dashboard for category sizing, plus a BioNixus study for the accounts, cities, SKUs, and traditional-trade channels the feed does not show.
Typical 2026 planning bands are custom research from $10,000 to $60,000. See the pricing page. A proposal is ready within 48 hours of a brief.
Continue
Project- and country-based ranges, plus /pricing.md.
OpenWhen the brief is pharma audits vs primary data.
OpenBrand-track vs account-level commercial research.
OpenFive questions to see what the dashboard still misses.
OpenBrand, SKU, market, and the Nielsen/IQVIA gap.
OpenNamed accounts we study when Nielsen undersamples bakals.
OpenWhat it is — primary vs syndicated, then country hubs.
OpenDubai and Abu Dhabi programmes for affiliates.
OpenAccount-level fieldwork in the largest MENA market.
OpenSFDA-aware primary studies vs syndicated audits.
OpenTell us the country, the accounts, and the SKU. Proposal ready within 48 hours of a brief.
Primary research, market access & HEOR. A 30-minute scoping call, then a costed proposal within 48 hours.
What happens on the call